Arcus Biosciences (RCUS) Peer Comparison

$18.14

$0.38 (2.14%)

As on 27-Oct-2026 16:10EDT

Market cap

$2,332 Mln

Revenue (TTM)

$117 Mln

P/E Ratio

--

P/B Ratio

6.8

Div. Yield

0 %

Edit

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	2,332	18,719	15,989	16,015	14,259
Revenue ($ Mln)	117	2,838	2,436	1,054	1,664
Net Profit ($ Mln)	-452.00	517.83	860.62	755.85	413.60
Net Margin (%)	-386.32	18.24	35.33	71.69	24.86
RoE (%)	-82.56	87.53	42.98	--	430.03
Price to Earnings	--	37.16	20.36	18.65	36.73
Price-To-Book	6.76	39.67	7.82	9.82	25.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Operating Revenue	117.00	2,838.39	2,435.92	1,054.37	1,663.74
Cost of Revenue	7.00	2,011.22	85.67	103.47	292.42
Gross Profit	237.00	760.62	2,236.43	588.53	1,167.84
Operating Expenses	596.00	220.03	1,378.74	841.45	440.53
Operating Profit (EBIT)	-486.00	607.14	971.51	109.45	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-452.00	626.99	1,035.47	101.11	583.34
Provision for Tax	0.00	109.17	174.84	-654.74	169.74
Profit after Tax (Net Income)	-452.00	517.83	860.62	755.85	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Shareholder's Funds	464.00	584.94	1,843.76	1,435.90	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	262.00	221.56	288.55	384.48	2,089.43
Current Liabilities	198.00	1,496.10	361.93	464.70	344.44
Total Liabilities	1,139.00	1,975.47	2,844.42	1,302.02	2,525.32

Assets ($ Mln)

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Non-Current Assets	168.00	1,057.60	1,243.41	895.24	1,644.38
Current Assets	756.00	1,245.00	1,250.82	1,389.84	933.02
Total Assets	1,139.00	1,975.47	2,844.42	1,302.02	2,525.32
Total Debt*	114.00	146.04	165.93	449.89	2,146.65
Net Current Assets	558.00	0.00	888.90	925.52	588.59

Cashflow ($ Mln)

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-482.00	713.22	884.27	51.77	651.56
Cash Flow from Investing Activities	66.00	-31.14	350.44	-8.15	-545.81
Cash from Financing Activities	488.00	-860.39	-969.59	34.89	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
ROCE (%)	-54.81	57.43	32.82	-30.01	15.61
ROE (%)	-82.56	87.53	42.98	163.18	430.03
ROA (%)	-37.56	15.73	29.32	31.68	16.19
EBIT Margin (%)	-366.67	21.70	41.82	5.73	36.28
Net Margin (%)	-386.32	18.24	35.33	71.69	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-55.34	20.35	9.23	114.85	41.15
EBIT Growth (%)	-46.92	18.61	29.37	136.39	-14.99
Net Profit Growth (%)	-47.71	19.59	42.89	378.76	-25.78
EPS Growth (%)	-20.88	28.06	50.42	353.27	-23.48
Book Value Growth (%)	-28.62	108.60	-0.70	816.12	-55.81

Valuation Ratios

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Price / Earnings	-7.25	36.06	15.79	-59.76	24.99
Price / Book Value	4.06	35.44	5.72	-80.42	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-5.05	27.88	12.44	-121.54	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debt to Equity	0.22	0.00	0.00	0.27	13.50
Short term debt to equity ratio	0.03	0.00	0.00	0.05	1.46
Current Ratio	3.82	0.83	3.46	2.99	2.71
Quick Ratio	3.82	0.83	3.38	2.32	2.31
Interest Coverage	-18.65	--	--	1.62	29.73

Operating Efficiency Ratios

	Arcus Biosciences (RCUS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debtors to sales (%)	30.77	15.77	13.74	21.25	27.40
Asset Turnover	0.10	0.86	0.83	0.44	0.65
Receivable days	30.31	50.42	43.48	85.52	98.04
Inventory Days	--	--	96.17	1,056.70	254.12
Payable days	1,095.75	6.26	147.97	331.01	24.86
Cash Conversion Cycle	--	--	-8.32	811.21	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly